Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Crossref dates: July 17, 2021. Publisher notice ↗
Citation-backed change ledger
Follow records added to PeptideScanner separately from revised profiles, corrections, and retractions. Every event keeps its date, before-and-after state, preserved version links, and supporting public sources.
Source-published notices
These are Crossref-attributed publisher or Retraction Watch notices, not PeptideScanner corrections. The source-event dates and PeptideScanner review date remain separate.
Crossref dates: July 17, 2021. Publisher notice ↗
Crossref dates: June 19, 2026 and August 1, 2026. Publisher notice ↗
Crossref dates: December 17, 2025 and February 1, 2026. Publisher notice ↗
Crossref dates: August 25, 2026. Publisher notice ↗
Crossref dates: March 1, 2022. Publisher notice ↗
Crossref dates: February 1, 2023. Publisher notice ↗
Preserved version history
These are the latest routine updates, status changes, corrections, and retractions. Before-and-after fields are derived from adjacent preserved public versions.
We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.
We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.
We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.
We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.
We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.
We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.
We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.
ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 40484968, with a metadata revision date of 2026-10-14. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.
Collection activity
These records entered PeptideScanner most recently. Their separately labeled cited source dates may be much older.
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.
The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.